References
- Giudicessi J, Ackerman M. Azithromycin and risk of sudden cardiac
death: Guilty as charged or falsely accused? Cleveland Clinic
Journal of Medicine . 2013;80(9):539-544.
- Gorelik E, Masarwa R, Perlman A, Rotshild V, Muszkat M, Matok I.
Systematic Review, Meta-analysis, and Network Meta-analysis of the
Cardiovascular Safety of Macrolides. Antimicrobial Agents and
Chemotherapy. 2018;62(6).
- Polgreen L, Riedle B, Cavanaugh J, Girotra S, London B, Schroeder M et
al. Estimated Cardiac Risk Associated With Macrolides and
Fluoroquinolones Decreases Substantially When Adjusting for Patient
Characteristics and Comorbidities. Journal of the American Heart
Association . 2018;7(9).
- Juurlink D. The cardiovascular safety of azithromycin. Canadian
Medical Association Journal . 2014;186(15):1127-1128.
- Chico R, Pittrof R, Greenwood B, Chandramohan D.
Azithromycin-chloroquine and the intermittent preventive treatment of
malaria in pregnancy. Malaria Journal . 2008;7(1).
- WHO policy brief for the implementation of intermittent preventive
treatment of malaria in pregnancy using sulfadoxine-pyrimethamine
(IPTp-SP) [Internet]. World Health Organization. 2014 [cited 1
June 2020]. Available from:
https://www.who.int/malaria/publications/atoz/policy_brief_iptp_sp_policy_recommendation/en/
- Kimani J, Phiri K, Kamiza S, Duparc S, Ayoub A, Rojo R et al. Efficacy
and Safety of Azithromycin-Chloroquine versus
Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of
Plasmodium falciparum Malaria Infection in Pregnant Women in Africa:
An Open-Label, Randomized Trial. PLOS ONE . 2016;11(6):e0157045.
- Timothy F. Simpson; Richard J. Kovacs; Eric C.
Stecker. Ventricular Arrhythmia Risk Due to
Hydroxychloroquine-Azithromycin Treatment For COVID-19 - American
College of Cardiology [Internet]. American College of Cardiology.
2020 [cited 1 June 2020]. Available from:
https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19
- Ridings JE. The thalidomide disaster, lessons from the past.
InTeratogenicity Testing. 2013; 575-586. Humana Press, Totowa, NJ.
- Kallen B. Maternal drug use in early pregnancy and infant
cardiovascular defect. Reproductive Toxicology .
2003;17(3):255-261.
- Källén B, Otterblad Olausson P, Danielsson B. Is erythromycin therapy
teratogenic in humans?. Reproductive Toxicology .
2005;20(2):209-214.
- Källén B, Danielsson B. Fetal safety of erythromycin. An update of
Swedish data. European Journal of Clinical Pharmacology.
2013;70(3):355-360.
- Fan H, Gilbert R, O’Callaghan F, Li L. Associations between macrolide
antibiotics prescribing during pregnancy and adverse child outcomes in
the UK: population based cohort study. BMJ . 2020;m331.
- Tellem R, Shechtman S, Arnon J. Pregnancy outcome after gestational
exposure to the new macrolides: a prospective controlled cohort study.Reproductive Toxicology . 2005; 20: 484-485.
- Bar-Oz B, Diav-Citrin O, Shechtman S, Tellem R, Arnon J, Francetic I
et al. Pregnancy outcome after gestational exposure to the new
macrolides: A prospective multi-center observational study.European Journal of Obstetrics & Gynecology and Reproductive
Biology . 2008;141(1):31-34.
- Cooper WO, Hernandez‐Diaz S, Arbogast PG, Dudley JA, Dyer SM, Gideon
PS, Hall KS, Kaltenbach LA, Ray WA. Antibiotics potentially used in
response to bioterrorism and the risk of major congenital
malformations. Paediatric and perinatal epidemiology .
2009;23(1):18-28.
- Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ.
Antibacterial medication use during pregnancy and risk of birth
defects: National Birth Defects Prevention Study. Archives of
pediatrics & adolescent medicine . 2009;163(11):978-85.
- Nordeng H, Romøren M, Lindbæk M. Safety of macrolides during
pregnancy—With special focus on erythromycin and congenital heart
malformations. Reproductive Toxicology . 2010;2(30):227.
- Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational
exposure to erythromycin–a population‐based register study from
Norway. British journal of clinical pharmacology .
2012;74(6):1053-62.
- Bar-Oz B, Weber-Schoendorfer C, Berlin M, Clementi M, Di Gianantonio
E, de Vries L, De Santis M, Merlob P, Stahl B, Eleftheriou G, Maňáková
E. The outcomes of pregnancy in women exposed to the new macrolides in
the first trimester. Drug safety . 2012;35(7):589-98.
- Lin KJ, Mitchell AA, Yau WP, Louik C, Hernández-Díaz S. Safety of
macrolides during pregnancy. American journal of obstetrics and
gynecology . 2013;208(3):221-e1.
- Andersen JT, Petersen M, Jimenez-Solem E, Rasmussen JN, Andersen NL,
Afzal S, Broedbaek K, Hjelvang BR, Køber L, Torp-Pedersen C, Poulsen
HE. Trimethoprim use prior to pregnancy and the risk of congenital
malformation: a register-based nationwide cohort study.Obstetrics and gynecology international . 2013;2013.
- Dinur AB, Koren G, Matok I, Wiznitzer A, Uziel E, Gorodischer R, Levy
A. Fetal safety of macrolides. Antimicrobial agents and
chemotherapy . 2013;57(7):3307-11.
- Bérard A, Sheehy O, Zhao JP, Nordeng H. Use of macrolides during
pregnancy and the risk of birth defects: a population‐based study.Pharmacoepidemiology and drug safety . 2015;24(12):1241-8.
- Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and
the risk of major congenital malformations: a population based cohort
study. British journal of clinical pharmacology .
2017;83(11):2557-71.
- Damkier P, Brønniche LM, Korch-Frandsen JF, Broe A. In utero exposure
to antibiotics and risk of congenital malformations: a
population-based study. American journal of obstetrics and
gynecology . 2019;221(6):648-e1.
- Czeizel AE, Rockenbauer M, Olsen J, SØRENSEN HT. A case-control
teratological study of spiramycin, roxithromycin, oleandomycin and
josamycin. Acta obstetricia et gynecologica Scandinavica .
2000;79(3):234-7.
- Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. A population-based
case-control teratologic study of oral erythromycin treatment during
pregnancy. Reproductive Toxicology . 1999;13(6):531-6.
- Mallah N, Tohidinik HR, Etminan M, Figueiras A, Takkouche B. Prenatal
Exposure to Macrolides and Risk of Congenital Malformations: A
Meta-Analysis. Drug safety . 2019;12:1-1.
- Khoury MJ, Moore CA, James LM, Cordero JF. The interaction between
dysmorphology and epidemiology: methodologic issues of lumping and
splitting. Teratology . 1992;45(2):133-8.
- EUROCAT guide 1.4 reference documents[Internet]. 2018 [cited 1
June 2020]. Available from:
https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/Full_Guide_1_4_version_28_DEC2018.pdf
- de Jong-van den Berg LT, Bakker MK, Dolk H. EUROmediCAT: European
surveillance of safety of medication use in pregnancy.Pharmacoepidemiology and Drug Safety . 2011;20(S1):S46-7.
- Greenlees R, Neville A, Addor MC, Amar E, Arriola L, Bakker M, Barisic
I, Boyd PA, Calzolari E, Doray B, Draper E. Paper 6: EUROCAT member
registries: organization and activities. Birth Defects Research Part
A: Clinical and Molecular Teratology. 2011;91(S1):S51-100.
- Bakker M, De Jonge L. EUROCAT Special Report: Sources of information
on medication use in pregnancy. EUROCAT Central Registry . 2014.
- Leke AZ. Maternal use and safety of anti-infectives in pregnancy, with
special reference to Cameroon (Doctoral dissertation, Ulster
University). 2017; Chapter 4, p159.
- Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology.Lippincott Williams & Wilkins . 2008.
- Hook EB. What kind of controls to use in case control studies of
malformed infants: recall bias versus “teratogen nonspecificity”
bias. Teratology . 2000;61(5):325-6.
- Poletta FA, Camelo JS, Gili JA, Leoncini E, Castilla EE, Mastroiacovo
P. Methodological approaches to evaluate teratogenic risk using birth
defect registries: advantages and disadvantages. PloS one .
2012;7(10).
- Webster R, Leishman D, Walker D. Towards a drug concentration effect
relationship for QT prolongation and torsades de pointes.Current opinion in drug discovery & development .
2002;5(1):116-26.
- Danielsson C, Brask J, Sköld AC, Genead R, Andersson A, Andersson U,
Stockling K, Pehrson R, Grinnemo KH, Salari S, Hellmold H. Exploration
of human, rat, and rabbit embryonic cardiomyocytes suggests K-channel
block as a common teratogenic mechanism. Cardiovascular
research . 2013;97(1):23-32.
- Davies MP, An RH, Doevendans P, Kubalak S, Chien KR, Kass RS.
Developmental changes in ionic channel activity in the embryonic
murine heart. Circulation research . 1996;78(1):15-25.
- Wang L, Feng ZP, Kondo CS, Sheldon RS, Duff HJ. Developmental changes
in the delayed rectifier K+ channels in mouse heart. Circulation
research . 1996;79(1):79-85.
- Abrahamsson C, Palmer M, Ljung B, Duker G, Bäärnhielm C, Carlsson L,
Danielsson B. Induction of rhythm abnormalities in the fetal rat
heart. A tentative mechanism for the embryotoxic effect of the class
III antiarrhythmic agent almokalant. Cardiovascular research .
1994;28(3):337-44.
- Jaffee OC. Hemodynamic factors in the development of the chick embryo
heart. The Anatomical Record . 1965;151(1):69-75.
- Hill AB. The environment and disease: association or causation?.Proc R Soc Med. 1965;58: 295-300.
- Louik C, Werler MM, Mitchell AA. Erythromycin use during pregnancy in
relation to pyloric stenosis. American journal of obstetrics and
gynecology . 2002;186(2):288-90.
- Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ,
Wohlfahrt J, Melbye M. Use of macrolides in mother and child and risk
of infantile hypertrophic pyloric stenosis: nationwide cohort study.Bmj . 2014;348:g1908.
- Cooper WO, Ray WA, Griffin MR. Prenatal prescription of macrolide
antibiotics and infantile hypertrophic pyloric stenosis.Obstetrics & Gynecology . 2002 Jul 1;100(1):101-6.
- Fan H, Li L, Wijlaars L, Gilbert RE. Associations between use of
macrolide antibiotics during pregnancy and adverse child outcomes: A
systematic review and meta-analysis. PloS one . 2019;14(2).
- Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a
reference guide to fetal and neonatal risk. Lippincott Williams
& Wilkins . 2012.
- Karabulut AK, Uysal II, Acar H, Fazliogullari Z. Investigation of
developmental toxicity and teratogenicity of macrolide antibiotics in
cultured rat embryos. Anatomia, histologia, embryologia. 2008
Oct;37(5):369-75.
- Medicines & Healthcare Products Regulatory Agency. Summary of Product
Characteristics: Clarithromycin 500mg film-coated tablets. 2019
[cited 1 June 2020]. Available from:
http://www.hpra.ie/img/uploaded/swedocuments/Licence_PA1347-068-002_13112019125315.pdf.
- Joint Formulary Committee. BNF 77 (British National Formulary) March
2019. Pharmaceutical Press; 2019.
- The Swedish Medical Products Agency. [Erythromycin should be avoided
during early pregnancy]. 2006. [cited 1 June 2020].
https://lakemedelsverket.se/Alla-nyheter/NYHETER-2005/Erytromycin-bor-undvikas-under-tidiggraviditet/.
- Garne E, Dolk H, Loane M, Eurocat PA. EUROCAT website data on prenatal
detection rates of congenital anomalies.2010.
- Petersen I, Gilbert R, Evans S, Ridolfi A, Nazareth I. Oral antibiotic
prescribing during pregnancy in primary care: UK population-based
study. Journal of antimicrobial chemotherapy.2010;65(10):2238-46.
- de Jonge L, Garne E, Gini R, Jordan SE, Klungsoyr K, Loane M, Neville
AJ, Pierini A, Puccini A, Thayer DS, Tucker D. Improving information
on maternal medication use by linking prescription data to congenital
anomaly registers: a EUROmediCAT study. Drug safety .
2015;38(11):1083-93.